Kynam Capital Management, LP
PRINCETON, NJ · CIK 1907884 · 13F filing filed 2023-08-14
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$2.4bn
- Staff3 · 2 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $2.4bn gross assets
- Form ADV · 2026-04-10SEC adviser record
- Legal entityKYNAM CAPITAL MANAGEMENT, LP (US)
- Kindhedge funds, futures
- Others nearbyPrinceton, NJ
As an employer
- Private fundshedge 1
$652.5m
reported value
-15.6% vs Q1 2023
23positions
84.1%in top 10
0 new
10 added
6 reduced
11 sold out
vs Q1 2023
Options: 2 call positions ($2.7m notional), 1 put positions ($71.8m notional) – listed below, not included above.
Holdings, Q2 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| NATERA INC NTRA | $141.1m21.63% | Reduced -18.2k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $88.2m13.52% | Added +1.2m |
| SYNDAX PHARMACEUTICALS INC SNDX | $68.3m10.46% | Added +56.0k |
| VAXCYTE INC PCVX | $64.9m9.95% | Added +83.2k |
| 2SEVENTY BIO INC TSVT | $49.5m7.59% | Added +1.2m |
| VERA THERAPEUTICS INC VERA | $48.1m7.38% | Reduced -372.4k |
| PROTAGONIST THERAPEUTICS INC PTGX | $26.9m4.13% | Reduced -399.7k |
| TRAVERE THERAPEUTICS INC TVTX | $22.3m3.42% | Reduced -108.9k |
| BIOCRYST PHARMACEUTICALS INC BCRX | $20.1m3.07% | Added +1.8m |
| COGENT BIOSCIENCES INC COGT | $19.1m2.93% | Added +1.2m |
| BURNING ROCK BIOTECH LTD SPONSORED ADS | $18.3m2.81% | Added +479.4k |
| VIRIDIAN THERAPEUTICS INC VRDN | $16.9m2.59% | Added +165.9k |
| WAVE LIFE SCIENCES LTD 96663EUR | $14.3m2.19% | Added +116.7k |
| AMARIN CORP PLC SPONS ADR NEW | $14.3m2.19% | Unchanged |
| LIQUIDIA CORPORATION LQDA | $12.9m1.98% | Unchanged |
| OLEMA PHARMACEUTICALS INC OLMA | $11.8m1.81% | Reduced -707.5k |
| SUTRO BIOPHARMA INC COM | $7.0m1.07% | Added +598.2k |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $4.5m0.69% | Unchanged |
| PUMA BIOTECHNOLOGY INC PBYI | $1.7m0.26% | Unchanged |
| RHYTHM PHARMACEUTICALS INC RYTM | $1.5m0.23% | Unchanged |
| CONNECT BIOPHARMA HLDGS LTD ADS | $602.6k0.09% | Reduced -204.6k |
| NEOLEUKIN THERAPEUTICS INC COM | $99.6k0.02% | Unchanged |
| CATALYST BIOSCIENCES INC COM NEW | $31.6k0.00% | Unchanged |
Sold out since Q1 2023
| Security | Value then |
|---|---|
| HORIZON THERAPEUTICS PUB L HZNP | $119.5m1.1m shares |
| SEAGEN INC SGEN | $20.2m100.0k shares |
| MIRATI THERAPEUTICS INC MRTX | $18.6m499.9k shares |
| GSK PLC GSK | $17.7m498.3k shares |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $11.0m1.8m shares |
| ALLOGENE THERAPEUTICS INC ALLO | $7.4m1.5m shares |
| SERES THERAPEUTICS INC | $4.4m768.9k shares |
| GOSSAMER BIO INC GOSS | $1.9m1.5m shares |
| XENON PHARMACEUTICALS INC XENE | $1.0m28.7k shares |
| ARCELLX INC ACLX | $965.5k31.3k shares |
| MERUS N V MRUS | $394.8k21.5k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| ARGENX SE ARGX · Put | $71.8m184.3k shares | Added |
| FIBROGEN INC Call | $1.6m586.5k shares | New |
| PTC THERAPEUTICS INC PTCT · Call | $1.2m28.5k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 | 14.0% |
| SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 | 10.0%≈ $186.2m |
| CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 | 10.0% |
| CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 | 6.8% |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 5.7% |
| SUTRO BIOPHARMA INC 13G · filed 2026-05-15 | 5.3% |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 | 5.3%≈ $56.7m |